Last reviewed · How we verify
Pegylated Interferon/ribavirin
Pegylated interferon works by stimulating the body's immune system to fight viral infections, while ribavirin is an antiviral medication that inhibits viral replication.
Pegylated interferon works by stimulating the body's immune system to fight viral infections, while ribavirin is an antiviral medication that inhibits viral replication. Used for Chronic hepatitis C, Chronic hepatitis C genotype 1.
At a glance
| Generic name | Pegylated Interferon/ribavirin |
|---|---|
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Drug class | Antiviral |
| Modality | Small molecule |
| Therapeutic area | Hepatology |
| Phase | Phase 3 |
Mechanism of action
Pegylated interferon is a type of protein that is used to stimulate the body's immune system to fight viral infections. Ribavirin, on the other hand, is an antiviral medication that works by inhibiting viral replication. When used together, they can help to reduce the amount of virus in the body and improve symptoms.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis C genotype 1
Common side effects
- Fatigue
- Headache
- Rash
- Nausea
- Diarrhea
Key clinical trials
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment (PHASE1)
- Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)
- Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) (PHASE2)
- Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy (PHASE4)
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (EARLY_PHASE1)
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants (PHASE2)
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |